Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series

Author(s): Giovanni Di Mauro, Giovanni Vietri, Loreta Quaranta, Fabio Placidi, Francesca Izzi, Alessandro Castelli, Andrea Pagano, Francesca Leonardis, Viviana De Angelis, Ciro Bianco, Maria Grazia Celeste, Nicola Biagio Mercuri and Claudio Liguori*

Volume 24, Issue 2, 2025

Published on: 21 June, 2024

Page: [158 - 163] Pages: 6

DOI: 10.2174/0118715273304077240603115521

Price: $65

TIMBC 2025
Abstract

Introduction: Refractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment for these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex.

Case Presentation: Here, we present two cases of effective use of hpCBD in both refractory and super- refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures.

Conclusion: According to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs.

Keywords: Status epilepticus, emergency, anti-seizure medication, epilepsy, seizure, lennox-gastaut syndrome.

« Previous Next »
Graphical Abstract

[1]
Trinka E, Leitinger M. Management of Status epilepticus, refractory status epilepticus, and super-refractory status epilepticus. Continuum (Minneap Minn) 2022; 28(2): 559-602.
[http://dx.doi.org/10.1212/CON.0000000000001103] [PMID: 35393970]
[2]
Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17(1): 3-23.
[http://dx.doi.org/10.1007/s12028-012-9695-z] [PMID: 22528274]
[3]
Lowenstein DH. The management of refractory status epilepticus: An update. Epilepsia 2006; 47(s1) (Suppl. 1): 35-40.
[http://dx.doi.org/10.1111/j.1528-1167.2006.00658.x] [PMID: 17044824]
[4]
Kirmani BF, Au K, Ayari L, John M, Shetty P, Delorenzo RJ. Super-refractory status epilepticus: Prognosis and recent advances in management. Aging Dis 2021; 12(4): 1097-119.
[http://dx.doi.org/10.14336/AD.2021.0302]
[5]
Rai S, Drislane FW. Treatment of refractory and super-refractory status epilepticus. Neurotherapeutics 2018; 15(3): 697-712.
[http://dx.doi.org/10.1007/s13311-018-0640-5] [PMID: 29922905]
[6]
Farrokh S, Bon J, Erdman M, Tesoro E. Use of newer anticonvulsants for the treatment of status epilepticus. Pharmacotherapy 2019; 39(3): 297-316.
[http://dx.doi.org/10.1002/phar.2229] [PMID: 30723940]
[7]
Ochoa JG, Dougherty M, Papanastassiou A, Gidal B, Mohamed I, Vossler DG. Treatment of super-refractory status epilepticus: A review. Epilepsy Curr 2021; 21(6): 405-15.
[http://dx.doi.org/10.1177/1535759721999670] [PMID: 33719651]
[8]
Tambe SM, Mali S, Amin PD, Oliveira M. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications. J Integr Med 2023; 21(3): 236-44.
[http://dx.doi.org/10.1016/j.joim.2023.03.004] [PMID: 36973157]
[9]
de Almeida DL, Devi LA. Diversity of molecular targets and signaling pathways for CBD. Pharmacol Res Perspect 2020; 8(6): e00682.
[http://dx.doi.org/10.1002/prp2.682] [PMID: 33169541]
[10]
Zurolo E, Iyer AM, Spliet WGM, et al. CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies. Neuroscience 2010; 170(1): 28-41.
[http://dx.doi.org/10.1016/j.neuroscience.2010.07.004] [PMID: 20621164]
[11]
Howlett AC, Abood ME. CB 1 and CB 2 receptor pharmacology. Adv Pharmacol 2017; 80: 169-206.
[http://dx.doi.org/10.1016/bs.apha.2017.03.007] [PMID: 28826534]
[12]
Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004; 143(2): 247-50.
[http://dx.doi.org/10.1038/sj.bjp.0705920] [PMID: 15313881]
[13]
De Gregorio D, McLaughlin RJ, Posa L, et al. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 2019; 160(1): 136-50.
[http://dx.doi.org/10.1097/j.pain.0000000000001386] [PMID: 30157131]
[14]
Turkanis SA, Smiley KA, Borys HK, Olsen DM, Karler R. An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats. Epilepsia 1979; 20(4): 351-63.
[http://dx.doi.org/10.1111/j.1528-1157.1979.tb04815.x] [PMID: 477630]
[15]
Pitkänen A, Lukasiuk K, Dudek FE, Staley KJ. Epileptogenesis. Cold Spring Harb Perspect Med 2015; 5(10): a022822.
[http://dx.doi.org/10.1101/cshperspect.a022822]
[16]
Britch SC, Babalonis S, Walsh SL. Cannabidiol: Pharmacology and therapeutic targets. Psychopharmacology (Berl) 2021; 238(1): 9-28.
[http://dx.doi.org/10.1007/s00213-020-05712-8] [PMID: 33221931]
[17]
Abbotts KSS, Ewell TR, Butterklee HM. Cannabidiol and cannabidiol metabolites: Pharmacokinetics, interaction with food, and influence on liver function. Nutrients 2022; 14(10): 2152.
[http://dx.doi.org/10.3390/nu14102152]
[18]
Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 2018; 32(11): 1053-67.
[http://dx.doi.org/10.1007/s40263-018-0578-5] [PMID: 30374683]
[19]
Rajaraman RR, Sankar R, Hussain SA. Successful use of pure cannabidiol for the treatment of super-refractory status epilepticus. Epilepsy Behav Case Rep 2018; 10: 141-4.
[http://dx.doi.org/10.1016/j.ebcr.2018.07.004]
[20]
Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med 2017; 376(21): 2011-20.
[http://dx.doi.org/10.1056/NEJMoa1611618] [PMID: 28538134]
[21]
Stockings E, Zagic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: A systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018; 89(7): 741-53.
[http://dx.doi.org/10.1136/jnnp-2017-317168] [PMID: 29511052]
[22]
Riva A, D’Onofrio G, Pisati A, et al. Cannabidiol add-on in glycosylphosphatidylinositol-related drug-resistant epilepsy. Cannabis Cannabinoid Res 2023; can.2022.0255.
[http://dx.doi.org/10.1089/can.2022.0255] [PMID: 36862522]
[23]
Fetta A, Crotti E, Campostrini E, et al. Cannabidiol in the acute phase of febrile infection‐related epilepsy syndrome (FIRES). Epilepsia Open 2023; 8(2): 685-91.
[http://dx.doi.org/10.1002/epi4.12740] [PMID: 37042946]
[24]
Duda J, Reinert JP. Cannabidiol in refractory status epilepticus: A review of clinical experiences. Seizure 2022; 103: 115-9.
[http://dx.doi.org/10.1016/j.seizure.2022.11.006] [PMID: 36399869]
[25]
Vicino W, Muccioli L, Pondrelli F, et al. Real-world experience with cannabidiol as add-on treatment in drug-resistant epilepsy. Seizure 2023; 111: 39-41.
[http://dx.doi.org/10.1016/j.seizure.2023.07.009] [PMID: 37506564]

Rights & Permissions Print Cite
Article Metrics
16
1
Wayfinder Image
TIMBC 2025
© 2025 Bentham Science Publishers | Privacy Policy